Phase I Clinical Trial of PCV24 in Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in adults aged 18 years and older. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, controlled Phase I clinical trial.
Epistemonikos ID: 41c32c61fbc2b1f3c8df538959d0395d95fec710
First added on: Jul 01, 2024